KR102014922B1 - Composition for improving digestive functions comprising glabridin from Liquorice - Google Patents
Composition for improving digestive functions comprising glabridin from Liquorice Download PDFInfo
- Publication number
- KR102014922B1 KR102014922B1 KR1020140105358A KR20140105358A KR102014922B1 KR 102014922 B1 KR102014922 B1 KR 102014922B1 KR 1020140105358 A KR1020140105358 A KR 1020140105358A KR 20140105358 A KR20140105358 A KR 20140105358A KR 102014922 B1 KR102014922 B1 KR 102014922B1
- Authority
- KR
- South Korea
- Prior art keywords
- licorice
- present
- derived
- composition
- glablidine
- Prior art date
Links
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title claims abstract description 56
- 230000001079 digestive effect Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 title claims description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 title abstract description 50
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title abstract description 7
- 235000011477 liquorice Nutrition 0.000 title abstract description 7
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 title description 2
- 229940093767 glabridin Drugs 0.000 title description 2
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 title description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 48
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 48
- 229940010454 licorice Drugs 0.000 claims abstract description 48
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 210000000941 bile Anatomy 0.000 claims abstract description 16
- 230000028327 secretion Effects 0.000 claims abstract description 15
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 241000202807 Glycyrrhiza Species 0.000 claims abstract 6
- 230000029087 digestion Effects 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 10
- 230000005176 gastrointestinal motility Effects 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000031200 bile acid secretion Effects 0.000 abstract description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 229940069445 licorice extract Drugs 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 201000006549 dyspepsia Diseases 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229960003699 evans blue Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960004085 mosapride Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- -1 maltose and sucrose Chemical compound 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008279 Dumping Syndrome Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000032395 Post gastric surgery syndrome Diseases 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000004550 soluble concentrate Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for improving digestive function using licorice-derived glablidine as an active ingredient, and specifically, to promote bile acid secretion and to improve digestive function comprising licorice-derived glabliine as an active ingredient, which has an effect of improving digestive function. The present invention relates to a composition for extracting glaglidine from licorice and licorice. The liquorice glabliine according to the present invention can be used very effectively for promoting bile secretion and improving gastrointestinal motility. In addition, the possibility of side effects due to long-term use is very safe.
Description
The present invention relates to a composition for improving digestive function using licorice-derived glablidine as an active ingredient, and specifically, to promote bile acid secretion and to improve digestive function comprising licorice-derived glabliine as an active ingredient, which has an effect of improving digestive function. The present invention relates to a composition for extracting glaglidine from licorice and licorice.
As the industry developed and rapidly modernized, the dietary life of modern man became westernized, and the change of dietary patterns caused disharmony in the metabolism of the human body. In addition, the intake of high-calorie foods, instant foods and high-fat foods increases, the intake of fiber, etc. is reduced, the lack of exercise due to the lifestyle to pursue a comfortable life, functional digestive disorders are becoming a big problem for modern people. . Functional digestive disorders are clinical syndromes in which the patient presents symptoms of the digestive system even when no organic lesions are found in the stomach itself, with the upper and lower gastrointestinal types being the type. In particular, overwhelmingly many upper gastrointestinal types in Korea include heartburn, burping, nausea, vomiting, indigestion, epigastric discomfort after eating, and gastric abdominal pain on an empty stomach. Disorders of the lower gastrointestinal tract include postoperative ileus, dumping syndrome after gastrectomy, irritable bowel syndrome in the lower gastrointestinal tract, constipation and diarrhea.
In practice, although various kinds of drugs are used in clinical practice, it is very difficult to prove the usefulness of drugs in functional dyspepsia, and the symptoms of functional dyspepsia are so diverse that it is difficult to objectively evaluate and analyze them. It should also be taken into account that most patients have a placebo effect of 30-50% in patients with functional dyspepsia. It is not yet proven drug that is effective in all patients with functional dyspepsia up, now, based on relief of the symptoms of drug which is widely used in functional dyspepsia are antacids, H 2 - receptor antagonist (H 2 -receptor antagonist), Prokinetics and the like (Sachs G, Spenney JG, et al; Physiol. Rev. 58, pp 106-173, 1978). Some of them have a gastric acid suppression effect as well as a relaxing effect on gastrointestinal smooth muscle, and the elderly complain of severe abdominal bloating following these medications. Some patients with functional dyspepsia also have gastrointestinal motility disorders. Various methods have been studied to solve this problem, and as a result, various health functional foods or foods have been developed. However, there are no health functional foods that effectively improve digestion.
Licorice () 草, Chinese Liquorice) is a perennial herb that belongs to the legume and is distributed in northeastern China, Siberia, Mongolia, and northern China. Roots and stems are used as a sweetener and as a treatment for gastric and duodenal ulcers. Since the action of other drugs are gentle, it is used for various purposes in one shot. In particular, the glabliine component in licorice has been used as a raw material for cosmetics because of the skin whitening activity, and antioxidant function and fat metabolism physiological activity function have been reported. However, there is no known function to improve digestion.
The present inventors have studied to develop a new functional food material or drug material according to this need, and as a result, the glaglidine as described above promotes bile secretion to help fat digestion, and to help exercise of the gastrointestinal tract. Confirmed that the present invention was completed.
Accordingly, the present inventors have completed the present invention by developing a healthy functional food composition for digestive function and a pharmaceutical composition for treating digestive disorders using licorice-derived glablidine as an active ingredient.
Accordingly, it is an object of the present invention to provide a dietary supplement for improving digestive function using licorice-derived glablidine as an active ingredient.
Still another object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of digestive disorders comprising licorice-derived glabliine as an active ingredient.
Still another object of the present invention is to provide a licorice extract manufacturing method comprising glablidine.
Still another object of the present invention is to provide licorice-derived glabliine having any one or more functions selected from the group consisting of bile secretion promotion, fat digestion improvement and gastrointestinal motility activating functions.
In order to achieve the above object, the present invention relates to a composition for improving digestive function using licorice-derived glabliine as an active ingredient, which promotes bile secretion to help fat digestion and helps exercise of the gastrointestinal tract. will be.
In order to achieve another object of the present invention, the present invention provides a pharmaceutical composition for the prevention and treatment of digestive disorders using licorice-derived glabliine as an active ingredient.
Hereinafter, the present invention will be described in detail.
The present invention includes a licorice extract comprising the licorice-derived glablidine represented by the following formula (1) as an active ingredient.
[Formula 1]
Glablidine of the present invention is characterized in that it is extracted from licorice.
Licorice uses the root and stem below as a sweetening agent and a treatment for gastric ulcer and duodenal ulcer. Since the action of other drugs are gentle, it is used for various purposes in one shot. Licorice extract contains high amounts of glablidine. The efficacy of glablidine is not only improved digestion in the present invention but also has whitening and wrinkle improvement and antioxidant function.
The health functional food of the present invention may be in the form of powder, granules, tablets, capsules, syrups or beverages.
The "health functional food composition" is a food prepared by adding the licorice extract-derived glablidine to a general food, or encapsulating, powdering, and suspension, and when ingesting it, has a health-specific effect, but a general medicine Unlike the food as a raw material there is no side effect that can occur when taking long-term use of the drug.
There is no particular limitation on the form and type of the health functional food. The form of the health food to which the glabliine or licorice extract including the glablidine may be added may be powder, granules, tablets, capsules, syrups or beverages, and the like. Dairy products including dairy products, ice cream, breads, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums, various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes. Includes all health foods from
The health functional food composition of the present invention may contain various flavors, natural carbohydrates, and the like as additional ingredients, as in general health foods. Natural carbohydrates described above are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
In addition to the above, the functional food composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the glaglidine or the extract of the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical, but is usually selected in the range of 0.01 to 10 parts by weight per 100 parts by weight of the composition of the present invention.
The dietary supplement for improving digestion function comprising the licorice-derived glablidine of the present invention as an active ingredient may have any one or more functions selected from the group consisting of bile secretion promotion, fat digestion improvement and gastrointestinal motility activation.
The present invention provides a pharmaceutical composition for preventing and treating digestive disorders comprising licorice-derived glablidine represented by Formula 1 as an active ingredient.
[Formula 1]
In the manufacture of the pharmaceutical of the present invention, the herbal extract may be used as such, but may be mixed with a pharmaceutically acceptable carrier, forming agent, diluent, etc., such as powders, granules, capsules or injections. It can also be produced in solid and liquid form. Specifically, it may be in the form of tablets, pills, granules, powders, sachets, elecils, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile powders, in particular oral administration. Preferred are formulations formulated for use.
Suitable formulations known in the art of the pharmaceutical compositions of the invention are preferably those disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, 2013. Carriers, excipients and diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil. In formulating the composition, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may be added to the composition by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, and the like. It is prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, utopsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
Glablidine of the present invention is characterized in that it is extracted from licorice.
Licorice uses the root and stem below as a sweetening agent and a treatment for gastric ulcer and duodenal ulcer. Since the action of other drugs are gentle, it is used for various purposes in one shot. Licorice extract contains high amounts of glablidine. The efficacy of glablidine is not only improved digestion in the present invention but also has whitening and wrinkle improvement and antioxidant function.
Digestive disorders of the present invention are gastrointestinal hyperkinesia, gastric emptying disorder, ulcerative colitis, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastric dyskinesia, cholecystitis, pancreatitis, duodenal ulcer, gastric ulcer, chronic gastritis, Gastroesophageal reflux disease and functional dyspepsia is characterized in that any one selected from the group consisting of.
The present invention
(a) extracting licorice by adding alcohol, water and alcohol, acetone or water and acetone to licorice;
(b) concentrating at high temperature under reduced pressure to remove alcohol or acetone;
(c) vacuum drying the obtained concentrate at high temperature; And
(d) providing a licorice extract production method comprising glablidine represented by the following formula (1) comprising the step of obtaining the homogeneous particles by using a sieve after the powder is compacted and evenly ground using the grinding mill obtained do.
[Formula 1]
The temperature conditions for removing the alcohol or acetone in the step (b) of the invention is in the range of 40 ℃ to 80 ℃, preferably in the range of 50 ℃ to 70 ℃. In addition, its temperature conditions are maintained for 3 to 9 hours to remove alcohol or acetone.
The concentrate obtained in step (c) of the invention is subjected to vacuum drying in the range from 40 ° C. to 80 ° C., preferably in the range from 50 ° C. to 70 ° C.
The above-mentioned "vacuum drying" is drying performed under reduced pressure to 1 atm or less, which means that the obtained concentrate is sealed in a drier and water is removed at a high temperature and low pressure.
The “grinding mill” consists of a rotating cylindrical body and is a machine for finely pulverizing material.
Glablidine weight extracted from the licorice of the present invention is characterized in that 1% to 20% of the total licorice extract weight.
The weight of the glablidine to the total weight of licorice extract is characterized in that 1% to 20%, preferably 2% to 10%.
Licorice extract extracted by the manufacturing method may be used as an adjuvant, an adjuvants used as an additive to improve the efficacy of the vaccine, an adjuvant to enhance the therapeutic efficacy, and a feed additive. .
In the case of an immunopotentiator, the licorice hot water extract provided by the present invention is produced in a lyophilized form, suspended in a diluent when used, and used as an injection. In the case of a vaccine adjuvant, oil or aluminum gel (used as an adjuvant of a vaccine) It is adsorbed on aluminum gel). In the case of adjuvant therapy is the same as in the case of an immune enhancer, when used as a feed additive is to use the licorice hot water extract provided by the present invention to make a powder form added to the feed.
The amount of licorice hot water extract used to show the immunopotentiation effect varies depending on the type of immune cells and animals, but it is 10 ㎍ / ml based on the volume of the formulation when used in the formulation of an immune enhancer, a vaccine adjuvant, an adjuvant, or a feed additive. It is preferred to be 1 mg / ml, and when the immune cell test is regarded as a process for selecting an adjuvant, the actual applied concentration should be based on the effective concentration in the experimental animal, and thus 100 μg based on the volume of the formulation. More preferably.
The present invention provides licorice-derived glablidine having any one or more functions selected from the group consisting of bile secretion promotion, fat digestion improvement, and gastrointestinal motility activating function.
Therefore, the present invention relates to a composition for improving digestive function using licorice-derived glabliine as an active ingredient, and specifically, a functional food containing licorice-derived glabliine as an active ingredient, promoting bile acid secretion and improving digestive function. A composition and a pharmaceutical composition. The liquorice glabliine according to the present invention can be used very effectively for promoting bile secretion and improving gastrointestinal motility. In addition, the side effects of long-term use is less likely to be very safe.
Figure 1 is a graph measuring the amount of bile secretion by orally administered to rats after the extraction of glabridine using water, acetone, ethanol as a solvent, respectively.
Hereinafter, the present invention will be described in detail.
However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
< Example 1>
Glablidine Licorice extract containing method
Dried Licorice ( Glycyrrhiza glabra ) roots were refluxed in a filter with acetone at 60 ° C. The filtrate was collected and concentrated for 6-7 hours at 50-60 ° C. under reduced pressure to remove acetone. The resulting water soluble concentrate was vacuum dried at 65-70 ° C. As a result, the obtained powder could be pulverized evenly with Grind and Mill, and homogeneous particles could be obtained using Sieve.
< Example 2>
Glablidine Confirmation of bile secretion increase effect of licorice extract
As a method for evaluating the bile secretion of licorice-derived glabliine according to the present invention, 7-week-old Spraugue-Dawley (SD) male rats were fasted for 24 hours, and then weighed. Licorice-derived glabliine extracted using a solvent was dissolved in water at a dose of 100 mg / kg and administered orally, and bile was collected at an hour after administration to measure bile secretion.
As a result, when the licorice-derived glablidine orally administered to rats as shown in the graph shown in Figure 1, it was observed that bile secretion significantly increased between 0-2 hours. In ethanol and acetone extracts, bile secretion was significantly increased.
< Example 3>
Distance from the intestine to the digestive tract GIT ( gastric intestinal transit ) Measurement
6-week-old male ICR rats were used as a method for evaluating digestive tract distance for licorice-derived glabridine according to the present invention and fasted for 24 hours, and water was supplied in a sufficient amount. After measuring the body weight, licorice-derived glabliine extracted with the control drug Metoclopride (Sigma-Aldrich) and various solvents was administered 30 minutes before administration of 5% evans blue, a substance that checks the distance to the digestive tract. Oral administration. Thirty minutes after 5% evans blue administration, the rats were dislocated from the cervical spine, and the abdomen of the rats was dissected along the midline, and the intestines were removed from the pyloric region to the rectum. The digestive tract was opened for easy measurement, and the distance from the pyloric region to the 5% evans blue tip was measured and the distance from the pyloric region to the rectum (total length of the digestive tract) was measured. In order to determine the gastrointestinal migration rate (T) of the administered 5% evans blue, the equation was calculated from the total length of the digestive tract (A) and the distance to the extreme end (B) of 5% evans blue. (T = (B / A) * 100 (%))
As a result, the distance of digestive tract was increased in ethanol extract and acetone extract. Therefore, it was confirmed that licorice-derived glabridine may help to improve digestive gastrointestinal motility.
(Significantly different from control. * P <0.05)
< Example 4>
top Discharge capacity GE ( gastric emptying ) Measurement
6 weeks old Spraugue-Dawley (SD) male rats were fasted for 24 hours, and water was supplied with sufficient amount. After weighing, the control drug Mosapride (Sigma-Aldrich) and licorice-derived glabliine of Experimental Example 1 were added 1.5 ml of 0.05% phenol red (w / v) as a gastric confirmatory substance. Oral administration 30 minutes before administration. Twenty minutes after oral administration of 0.05% phenol red (w / v), it was opened under ether anesthesia, and the stomach was removed after ligation of the pyloric and veneers. The extracted stomach was homogenized in 3 ml of 0.01N NaOH, and 0.2 ml of 20% trichloroacetic acid (w / v) was added to 1 ml of the homogenate to precipitate the protein and centrifuged for 20 minutes at a speed of 1,600 g. After centrifugation, 0.8 ml of 0.5N NaOH was added to 0.6 ml of the supernatant, and the absorbance was measured at 560 nm.
After oral administration of licorice-derived glablidine and Mosapride, ethanol and acetone extracts showed increased excretion capacity compared to the control group. It was confirmed that the gastric emptying effect was equal or better than that of the positive control Mosapride.
(Significantly different from control. * P <0.05, *** p <0.001)
< Example 5>
On the rat About Acute oral administration Toxicity Test
Acute toxicity test was performed on the licorice-derived glabliine of Example 1 using a 6-week-old SPF SD male and female rat. The experimental group consisted of the licorice-derived glabliine of the present invention in dose groups of 1 g / kg, 2 g / kg and 5 g / kg for 5 male and female animals per group, and the test substance was 5% HPMC (hydroxypropylmethyl). suspended in cellulose) solution and orally administered once. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and blood biochemical tests were performed.
As a result, no significant clinical symptoms or dead animals were noted in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings. In addition, as a result of comparing the microscopic findings of the experimental group to which the licorice-derived glablidine of the present invention was administered and the control group not to the administration, real organs such as liver, spleen, kidney, brain, skin, reproductive system, stomach, large intestine, heart and lung It was confirmed that the extract of the present invention, etc. do not show toxicity. As a result, all of the extracts of the present invention tested were determined to be safe substances that do not show toxic changes in rats up to 5 g / kg.
< Example 6>
Digestive Function
The test was performed on 50 patients with normal digestive problems. Specifically, licorice-derived glablidine extracted according to Example 1 was orally administered to 25 patients, and the remaining 25 were orally administered only the composition except the glablidine component as a control. This clinical trial was conducted with a blind test, and a questionnaire related to digestive dysfunction was checked for improvement of digestive function.
As a result, a significant improvement in digestive function was observed in the oral administration of the composition containing liquorice-derived glabridine, and it was difficult to confirm the significant result in the control group.
Licorice-derived glabliine according to the present invention can be used very effectively for promoting bile secretion and improving gastrointestinal motility. In addition, the possibility of side effects due to long-term use is small, so the industrial applicability is great.
Claims (9)
[Formula 1]
[Formula 1]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140105358A KR102014922B1 (en) | 2014-08-13 | 2014-08-13 | Composition for improving digestive functions comprising glabridin from Liquorice |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140105358A KR102014922B1 (en) | 2014-08-13 | 2014-08-13 | Composition for improving digestive functions comprising glabridin from Liquorice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160020261A KR20160020261A (en) | 2016-02-23 |
| KR102014922B1 true KR102014922B1 (en) | 2019-08-27 |
Family
ID=55449186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140105358A KR102014922B1 (en) | 2014-08-13 | 2014-08-13 | Composition for improving digestive functions comprising glabridin from Liquorice |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102014922B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230141995A (en) | 2022-03-30 | 2023-10-11 | 박형범 | Composition for improving digestive functions comprising a mixed plant extract powder as an active ingredient |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102407619B1 (en) * | 2020-03-24 | 2022-06-13 | (주)에이앤바이오 | Composition for improving cat hairball discharge |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100570803B1 (en) * | 2003-01-21 | 2006-04-13 | 학교법인 인하학원 | A process of extracting glabridine from licorice root |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101263191B1 (en) * | 2010-05-06 | 2013-05-10 | 주식회사 사이그린 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
-
2014
- 2014-08-13 KR KR1020140105358A patent/KR102014922B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100570803B1 (en) * | 2003-01-21 | 2006-04-13 | 학교법인 인하학원 | A process of extracting glabridine from licorice root |
Non-Patent Citations (1)
| Title |
|---|
| Life Sciences.2002, Vol.71, pp.1449-1463 1부* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230141995A (en) | 2022-03-30 | 2023-10-11 | 박형범 | Composition for improving digestive functions comprising a mixed plant extract powder as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160020261A (en) | 2016-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
| KR101565964B1 (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
| KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
| KR101263191B1 (en) | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease | |
| KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
| KR100542876B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
| KR101521341B1 (en) | Composition for prevention or treatment of anorexia comprising menispermum dauricum DC, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperum dauricum DC malt fermented liquid extract | |
| KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
| KR20100064519A (en) | Composition comprising the extract of soybean leaves for the prevention, delay or treatment of gout | |
| KR102410771B1 (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
| KR101016837B1 (en) | Composition comprising the extract of Lonicera japonica THUNB. preventing and treating arthritis | |
| KR100892180B1 (en) | Composition comprising powder of tangerine peel or the extract thereof for treating and preventing gastrointestinal disease | |
| WO2013187576A1 (en) | Composition comprising silymarin as active ingredient for preventing and treating peptic ulcers caused by alcohol consumption | |
| KR101181347B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dictamnus dasycarpus as active ingredient | |
| JP2020504144A (en) | Composition for preventing or treating gastritis or peptic ulcer | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR101241338B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing extracts of Polygonum aviculare as active ingredient | |
| WO2005094858A1 (en) | Antidiabetic composition | |
| KR102379574B1 (en) | Composition for preventing or treating sarcopenia comprising curcuma extract | |
| KR20120073797A (en) | Pharmaceutical composition comprising for preventing and treating an articular rheumatism, extract from the mixture of ponciri fructus, lonicerae flos and angelicae dahuricae radix | |
| KR20110012696A (en) | Food composition for stress relaxation, fatigue recovery or athletic performance enhancement comprising extract of root of vitis | |
| KR101144232B1 (en) | Blueberry extracts as an effective components for prevention and treatment of Hyperuricemia | |
| KR102019974B1 (en) | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion | |
| KR20150048698A (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |